CDNA Alert: Berman Tabacco Announces Investigation of CareDx, Inc. in Connection with Government Inquiries
Boston, Massachusetts--(Newsfile Corp. - October 29, 2021) - Berman Tabacco, a national law firm representing investors, is investigating potential securities law violations by CareDx, Inc. ("CareDx" or the "Company") (NASDAQ: CDNA), purports to be a "precision medicine company" which "offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients." The Company's headquarters are in South San Francisco, California.
On January 25, 2021, the Company sold 1,923,077 shares of its common stock through an underwritten public offering at a public offering price of $91.00 per share.
On October 28, 2021, after the market close, the Company disclosed in a Form 10-Q filed with the U.S. Securities and Exchange Commission ("SEC") that it was the subject on investigation by the U.S. Department of Justice and SEC. The Company stated in relevant part as follows:
The Company recently received a civil investigative demand (CID) from the United States Department of Justice (DOJ) requesting that the Company produce certain documents in connection with a False Claims Act investigation being conducted by the DOJ regarding certain business practices related to our kidney testing and phlebotomy services, and a subpoena from the United States Securities and Exchange Commission (SEC) in relation to an investigation by the SEC in respect of matters similar to those identified in the CID, as well as certain of our accounting and public reporting practices. The Company also received an information request from a state regulatory agency and may receive additional requests for information from the DOJ, SEC, or other regulatory and governmental agencies regarding similar or related subject matters.
The Company further noted, "Although the Company remains committed to compliance with all applicable laws and regulations, it cannot predict the outcome of the DOJ or SEC investigations, the state law information request, or any other requests or investigations that may arise in the future regarding these or other subject matters."
If you purchased CareDx securities and have sustained losses, and would like to discuss your legal rights, or if you wish simply to share information about the investigation, please visit: https://www.bermantabacco.com/case/caredx-inc/.
Berman Tabacco is a national law firm representing institutions and individuals in lawsuits, seeking to recoup losses caused by corporate and board misconduct and violations of the securities and antitrust laws. The firm has offices in Boston, Massachusetts and San Francisco, California.
This notice may constitute attorney advertising.
Contact:
Jay Eng, Esq.
(800) 516-9926
Email: law@bermantabacco.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/101382
